Evaluating the Efficacy and Safety of Venous Flow-Through Flaps in Hand Reconstructive Surgery: A Systematic Review.

Ann Plast SurgJun 29, 2026 (epub)
Clinical ResearchPlastic SurgeryGeneral Surgery

Barite Gutama, Valbona Lumani, Erin N Abbott et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the efficacy and safety of venous flow-through (VFT) flaps in upper extremity reconstructive surgery, analyzing 62 studies involving 999 patients. The overall flap survival rate was 96.74%, while the complication rate was 32.73%, with common issues including venous congestion and partial necrosis.

Key findings

  • Overall survival rate of VFT flaps was 96.74% (95% CI: 95.62-97.88).
  • The complication rate was 32.73% (95% CI: 29.89-35.70), with venous congestion occurring in 6.81% of cases.
  • Flap failure occurred in 2.50% (95% CI: 1.70-3.67) of patients.

Why it matters

Understanding the outcomes and complications associated with VFT flaps can guide clinicians in making informed decisions regarding reconstructive options for upper extremity injuries, ultimately improving patient care and surgical outcomes.

Source

PubMed · PMID 42372219

Published in Ann Plast Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Plastic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.